SEC Form 4 · accession 0001607737-26-000013
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Renee D Gala
Officer — President & CEO
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 4:33 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 8, 2026 | F | 1,967 | $246.81 | D | 145,394 | D | |
| Ordinary Shares | Sep 8, 2026 | S | 2,000 | $243.03 | D | 143,394 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- F2This transaction was made pursuant to a plan adopted by the reporting person on June 4, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.